SynAct Pharma

BioStock has published an article following SynAct's recent Capital Markets Day. Read the full article in English here: https://lnkd.in/dJ5QNJ27

SynAct’s abstract for resomelagon (AP1189) that is set to be presented at the American College of Rheumatology (ACR) Convergence 2024 conference, being held in Washington DC, USA, from November 14 to 19 is now online.    “We look very much forward to presenting the EXPAND-study clinical data at the ACR Convergence 2024, the world's premier rheumatology event,” said SynAct’s CSO Thomas Jonassen. “The development of resomelagon (AP1189) in the patient population is continued in the Phase 2b ADVANCE study.” View the abstract here: https://lnkd.in/dDA9hSqq

Listen in to SynAct Pharma’s Capital Markets Day held on September 23 in Stockholm and hear the management team, board members and guest speakers present the latest plans for how the company is resolving inflammation through selective activation of the melanocortin system. https://lnkd.in/drEiYt8J

Don't forget to signup to join SynAct Pharma at its CMD on September 23 in Stockholm to hear the latest plans for how the company is resolving inflammation through selective activation of the melanocortin system. https://lnkd.in/drEiYt8J

SynAct Pharma to present clinical data on resomelagon (AP1189) at ACR Convergence “We look very much forward to presenting the EXPAND-study clinical data at the ACR Convergence 2024, the world's premier rheumatology event,” said SynAct’s CSO Thomas Jonassen. “The development of resomelagon (AP1189) in the patient population is continued in the Phase 2b ADVANCE study.” https://lnkd.in/dQXnWDs2

Come join SynAct Pharma at its CMD on September 23 in Stockholm to hear the latest plans for how the company is resolving inflammation through selective activation of the melanocortin system. https://lnkd.in/dqBNfyb7

SynAct's CEO Jeppe Øvlesen spoke to BioStock about the company initiating the filing process for a new clinical phase IIb study with resomelagon in patients with severe, newly diagnosed RA with signs of systemic inflammation. Read the interview with BioStock here: https://lnkd.in/d6aQdBwg

SynAct Pharma today announced it has initiated a filing process in the US for the clinical Phase 2b ADVANCE study with resomelagon in patients with severe newly diagnosed RA.   “The submission is a part of the ambitious schedule that has been laid out in collaboration with our CRO and advisors to continue the development of resomelagon (AP1189) in RA. Our team and CRO have done a tremendous effort in getting the project back on track,” said Jeppe Øvlesen, CEO at SynAct Pharma.    The submission in the US will be followed by submission of clinical trials applications in Europe in the upcoming weeks. It is the intention to have active recruitment up running in late Q3 2024 with enrolment of all patients to be completed in Q4 2025. Read the press release here https://lnkd.in/dcHp2kp3

Since the EGM in March, SynAct Pharma has signed a contract with a CRO and aims to submit a Clinical Trial Application this quarter for the upcoming clinical phase IIb study with resomelagon. Furthermore, the company has conducted a capital raise of SEK 49 million, and the new board and management team are working to reduce costs. – Together, the new team is more focused and ready to move fast, CEO Jeppe Øvlesen told BioStock. Read the interview with BioStock here https://lnkd.in/dFPgk34X The interview is also available in Swedish here https://lnkd.in/dxC5VbF9 #SynAct #CEO #biotech #Biostock

Synact's CSO Thomas Jonassen has made an interview with Biostock where he gives his view on the further development of resomelagons for the treatment of RA and the strategic way forward. "Following the completion of the BEGIN, EXPAND and part A of the RESOLVE study we now know much more about the possibilities to develop resomelagon in Rheumatoid Arthritis (RA). A straightforward and clinically very interesting way would be to continue development of the compound as a Glucocorticoid (GC) and TNF-blocker sparing agent," said Thomas Jonassen Read the interview on the link below https://lnkd.in/dDJCd33N #SynAct #biotech #science #biostock